Clinicopathological significance and potential drug target of RUNX3 in breast cancer

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2423-2430

  Yu, Ying Ying ^a   Chen, Chao ^b   Kong, Fan Fei ^b   Zhang, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

Meta analysis; Methylation; Odds ratio; Tumor suppressor gene

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; TRANSCRIPTION FACTOR RUNX3; RUNX3 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL LINE; CANCER PATIENT; CANCER PROGNOSIS; CORRELATION COEFFICIENT; CPG ISLAND; DNA METHYLATION; DRUG TARGETING; FOLLOW UP; GENE EXPRESSION; HAZARD RATIO; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PUBLISHING; QUALITY CONTROL; REGRESSION ANALYSIS; RUNX3 GENE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; META ANALYSIS; METABOLISM; SURVIVAL ANALYSIS;

BREAST NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; FEMALE; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84916880893     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S71815     Document Type: Article

References (55)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113-126.
3. Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. Breast. 2013;22 Suppl 2:S50-S56.
4. Ozaki T, Nakagawara A, Nagase H. RUNX Family participates in the regulation of p53-dependent DNA damage response. Int J Genomics. 2013;2013:271347.
5. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res. 2008;99:33-76.
6. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5:376-387.
7. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 2009;1796:315-331.
8. Lund AH, van Lohuizen M. RUNX: a trilogy of cancer genes. Cancer Cell. 2002;1:213-215.
9. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics. 1994;23:425-432.
10. Chi XZ, Kim J, Lee YH, et al. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res. 2009;69:8111-8119.
11. Shiraha H, Nishina S, Yamamoto K. Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem. 2011;112:745-749.
12. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113-124.
13. Chi XZ, Yang JO, Lee KY, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol. 2005;25:8097-8107.
14. Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005;65:4809-4816.
15. Chen LF. Tumor suppressor function of RUNX3 in breast cancer. J Cell Biochem. 2012;113:1470-1477.
16. Tanaka S, Shiraha H, Nakanishi Y, et al. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer. 2012;131:2537-2546.
17. Li J, Jiang X. Loss of runt-related transcription factor 3 expression associated with human hepatocellular carcinoma progression and prognosis. Asian Pac J Cancer Prev. 2011;12:2285-2290.
18. Voon DC, Wang H, Koo JK, et al. Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells. 2012;30:2088-2099.
19. Voon DC, Wang H, Koo JK, et al. EMT-induced stemness and tumorigenicity are fueled by the EGFR/Ras pathway. PloS One. 2013;8:e70427.
20. Liu Z, Chen L, Zhang X, et al. RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells. J Cell Mol Med. 2014;18:610-623.
21. Subramaniam MM, Chan JY, Omar MF, et al. Lack of RUNX3 inactivation in columnar cell lesions of breast. Histopathology. 2010;57:555-563.
22. Huang B, Qu Z, Ong CW, et al. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene. 2012;31:527-534.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184.
24. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705-719.
25. Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725-731.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
28. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15:1237-1248; discussion 49-52.
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
30. Chuang LS, Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene. 2010;29:2605-2615.
31. Lee JH, Pyon JK, Kim DW, et al. Expression of RUNX3 in skin cancers. Clin Exp Dermatol. 2011;36:769-774.
32. Lee JM, Shin JO, Cho KW, et al. Runx3 is a crucial regulator of alveolar differentiation and lung tumorigenesis in mice. Differentiation. 2011;81:261-268.
33. Lee YM. Control of RUNX3 by histone methyltransferases. J Cell Biochem. 2011;112:394-400.
34. Levanon D, Brenner O, Otto F, Groner Y. Runx3 knockouts and stomach cancer. EMBO Rep. 2003;4:560-564.
35. Lee YS, Lee JW, Jang JW, et al. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell. 2013;24:603-616.
36. Araki K, Osaki M, Nagahama Y, et al. Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. Cancer Sci. 2005;96:227-231.
37. Subramaniam MM, Chan JY, Soong R, et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 2009;113:113-121.
38. Hwang KT, Han W, Bae JY, et al. Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer. J Korean Med Sci. 2007;22 Suppl:S24-S31.
39. Mu WP, Wang J, Niu Q, Shi N, Lian HF. Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis. Onco Targets Ther. 2014;7:1237-1245.
40. Yang Y, Ye Z, Zou Z, Xiao G, Luo G, Yang H. Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma. Tumour Biol. 2014;19:19.
41. Kang HF, Dai ZJ, Bai HP, et al. RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line. Onco Targets Ther. 2013;6:411-417.
42. Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66:6512-6520.
43. Chen W, Salto-Tellez M, Palanisamy N, et al. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes Cancer. 2007;46:288-301.
44. Delpu Y, Cordelier P, Cho WC, Torrisani J. DNA methylation and cancer diagnosis. Int J Mol Sci. 2013;14:15029-15058.
45. Ma X, Wang YW, Zhang MQ, Gazdar AF. DNA methylation data analysis and its application to cancer research. Epigenomics. 2013;5:301-316.
46. Lee SH, Bae SC, Kim KW, Lee YM. RUNX3 inhibits hypoxia-inducible factor-1α protein stability by interacting with prolyl hydroxylases in gastric cancer cells. Oncogene. 2014;33(11):1458-1467.
47. Yamada C, Ozaki T, Ando K, et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem. 2010;285:16693-16703.
48. Li DX, Wu H, Gao JZ, Fang ZX. Relationship between methylation status of Runx3 gene promoter and Runx3 protein expression in patients with breast cancer. China Maternal and Child Health. 2013;28:3650-3653.
49. Park SY, Kwon HJ, Choi Y, et al. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod Pathol. 2012;25:185-196.
50. Qiao L, Yang ZY, Liu W. Clinical significance of detecting plasma Runx3 gene promoter methylation in early diagnosis breast cancer. Mod Lab Med. 2012;27:35-37.
51. Park SY, Kwon HJ, Lee HE, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 2011;458:73-84.
52. Du JR, Lou G, Jiang Y. Relationship between the methylation of RUNX3 promoter and the clinical pathological characters and prognostic factors of breast invasive ductal carcinoma. Journal of Harbin Medical University. 2008;1:019.
53. Tian SW, Jia SC, Chen J. Analysis of the status of Runx3 gene promoter methylation in breast cancer and its relationship with pathological features. Chin J Breast Dis. 2010;4:50-53.
54. Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology. 2008;75:244-251.
55. Suzuki M, Shigematsu H, Shames DS, et al. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer. 2005;93:1029-1037.